TY - JOUR
T1 - Sleep impairment in allergic rhinitis, rhinosinusitis, and nasal polyposis
AU - Craig, Timothy
AU - Ferguson, Berrylin J.
AU - Krouse, John H.
N1 - Funding Information:
Declaration of funding/authors' financial relationships: Funding for this manuscript was provided by Schering-Plough Corporation. Timothy Craig is an advisory board member for Sanofi-Aventis; is on the speakers' bureau for Merck, Genentech/Novartis, GlaxoSmithKline, Schering Plough, and TEVA; and receives research support from Schering Plough, Merck, GlaxoSmithKline, Methapharm, AstraZeneca, Boehringer-Ingelheim, Novartis/Genentech, Dyax, Lev Pharmaceuticals, PDL, Centocor, Sanofi-Aventis, Alcon, and Altana. Berrylin J. Ferguson is an advisory board member or consultant for GlaxoSmithKline, Sanofi-Aventis, and Critical Therapeutics; is on the speakers' bureau for GlaxoSmithKline, Sanofi-Aventis, Merck, and Schering-Plough; and receives research support from GlaxoSmithKline. John H. Krouse is a consultant for Alcon, Sanofi-Aventis, Schering-Plough, and Medtronic; is on the speakers' bureau for Alcon, Sanofi-Aventis, Schering-Plough, and Merck; and receives research support from Schering-Plough. He also holds shares in Medtronic, Schering-Plough, and Alcon.
PY - 2008/5
Y1 - 2008/5
N2 - Sleep impairment is a significant problem for patients with inflammatory disorders of the upper respiratory tract, such as allergic rhinitis, rhinosinusitis, and nasal polyposis. Nasal congestion, one of the most common and bothersome symptoms of these conditions, is associated with sleep-disordered breathing and is thought to be a key cause of sleep impairment. This review examines sleep impairment associated with allergic rhinitis, rhinosinusitis, and nasal polyposis. It explores the adverse effects of disturbed sleep on patients' quality of life and how these inflammatory nasal conditions can be reduced by therapies that address the underlying problems affecting sleep. Treatment with intranasal corticosteroids has been shown to reduce nasal congestion in inflammatory disorders of the upper respiratory tract. Data on sleep-related end points from clinical trials of intranasal corticosteroids indicate that this reduction is associated with improved sleep, reduced daytime fatigue, and improved quality of life. Further research using measures of sleep as primary end points is warranted, based on the potential of these agents to improve sleep and quality of life in patients with allergic rhinitis, acute rhinosinusitis, and nasal polyposis. Such trials will help to identify the most effective therapies for sleep impairment in these 3 nasal conditions.
AB - Sleep impairment is a significant problem for patients with inflammatory disorders of the upper respiratory tract, such as allergic rhinitis, rhinosinusitis, and nasal polyposis. Nasal congestion, one of the most common and bothersome symptoms of these conditions, is associated with sleep-disordered breathing and is thought to be a key cause of sleep impairment. This review examines sleep impairment associated with allergic rhinitis, rhinosinusitis, and nasal polyposis. It explores the adverse effects of disturbed sleep on patients' quality of life and how these inflammatory nasal conditions can be reduced by therapies that address the underlying problems affecting sleep. Treatment with intranasal corticosteroids has been shown to reduce nasal congestion in inflammatory disorders of the upper respiratory tract. Data on sleep-related end points from clinical trials of intranasal corticosteroids indicate that this reduction is associated with improved sleep, reduced daytime fatigue, and improved quality of life. Further research using measures of sleep as primary end points is warranted, based on the potential of these agents to improve sleep and quality of life in patients with allergic rhinitis, acute rhinosinusitis, and nasal polyposis. Such trials will help to identify the most effective therapies for sleep impairment in these 3 nasal conditions.
UR - http://www.scopus.com/inward/record.url?scp=42749091322&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=42749091322&partnerID=8YFLogxK
U2 - 10.1016/j.amjoto.2007.06.002
DO - 10.1016/j.amjoto.2007.06.002
M3 - Article
C2 - 18439959
AN - SCOPUS:42749091322
SN - 0196-0709
VL - 29
SP - 209
EP - 217
JO - American Journal of Otolaryngology - Head and Neck Medicine and Surgery
JF - American Journal of Otolaryngology - Head and Neck Medicine and Surgery
IS - 3
ER -